Methylation profiling in early-stage NSCLC might become a diagnostic and prognostic biomarker in analogy to breast cancer: Aberrant methylation profiles of five genes (APC, CDH13, KLK10, DLEC1, RASSF1A) in cfDNA from 110 early-stage mixed entity NSCLC cases showed a significantly higher tumor-specific hypermethylation frequency when compared to healthy controls, reaching 83.64% sensitivity and 74% specificity to diagnose LC (89). This evidence concerns the gene CDH13 and neoplasm.